Financial reports
10-K
2023 FY
Annual report
29 Feb 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
17 Mar 23
10-Q
2022 Q3
Quarterly report
4 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
6 May 22
Current reports
8-K
Unregistered Sales of Equity Securities
18 Mar 24
8-K
Entry into a Material Definitive Agreement
6 Mar 24
8-K
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
4 Mar 24
8-K
Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
29 Feb 24
8-K
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
18 Dec 23
8-K
Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
13 Nov 23
8-K
Regulation FD Disclosure
10 Oct 23
8-K
Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
11 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
26 Jun 23
8-K
Results of Operations and Financial Condition
5 Jun 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
6 Mar 24
424B5
Prospectus supplement for primary offering
4 Mar 24
S-8
Registration of securities for employees
29 Feb 24
424B5
Prospectus supplement for primary offering
17 May 23
S-8
Registration of securities for employees
17 Mar 23
424B5
Prospectus supplement for primary offering
17 Mar 23
424B5
Prospectus supplement for primary offering
15 Sep 22
424B5
Prospectus supplement for primary offering
13 Sep 22
424B5
Prospectus supplement for primary offering
16 Jun 22
S-8
Registration of securities for employees
1 Mar 22
Proxies
Other
EFFECT
Notice of effectiveness
8 Jul 20
CORRESP
Correspondence with SEC
6 Jul 20
CORRESP
Correspondence with SEC
6 Jul 20
UPLOAD
Letter from SEC
20 May 20
CT ORDER
Confidential treatment order
21 Jun 19
EFFECT
Notice of effectiveness
20 Jun 19
CERT
Certification of approval for exchange listing
19 Jun 19
CORRESP
Correspondence with SEC
17 Jun 19
CORRESP
Correspondence with SEC
17 Jun 19
CORRESP
Correspondence with SEC
24 May 19
Ownership
4
Jonathan Young
3 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
Catriona Yale
15 Mar 24
4
William Richard White
15 Mar 24
4
Andrew Cheng
15 Mar 24
4
Jonathan Young
15 Mar 24
4
Timothy Rolph
15 Mar 24
SC 13G
GENERAL ATLANTIC, L.P.
15 Mar 24
4
Andrew Cheng
6 Mar 24
4
Catriona Yale
6 Mar 24